Qualigen Therapeutics, Inc. — Director's Dealing 2016

Oct 25, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RITTER PHARMACEUTICALS INC (RTTR)
CIK: 0001460702
Period of Report: 2016-10-25

Reporting Person: Ritter Andrew J (Director, President, 10% Owner)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-10-25	Non-qualified Stock Option (Right to Buy)	$2.60	A	140044	Acquired	2026-10-25	Common Stock (140044)	Direct

Footnotes

F1: The option vests ratably over 48 months following the public disclosure of top-line data results from the Issuer's Phase 2b/3 clinical trial.